Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P04035: Variant p.Gly822Asp

3-hydroxy-3-methylglutaryl-coenzyme A reductase
Gene: HMGCR
Feedback?
Variant information Variant position: help 822 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Glycine (G) to Aspartate (D) at position 822 (G822D, p.Gly822Asp). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from glycine (G) to medium size and acidic (D) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In LGMDR28; likely pathogenic; decreased hydroxymethylglutaryl-CoA reductase (NADPH) activity; reduced Vmax for hydroxymethylglutaryl-CoA reductase (NADPH) activity; has very low affinity for pravastatin. Any additional useful information about the variant.


Sequence information Variant position: help 822 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 888 The length of the canonical sequence.
Location on the sequence: help IGTVGGGTNLLPQQACLQML G VQGACKDNPGENARQLARIV The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         IGTVGGGTNLLPQQACLQMLGVQGACKDNPGENARQLARIV

Mouse                         IGTVGGGTNLLPQQACLQMLGVQGACKDNPGENARQLARIV

Rat                           IGTVGGGTNLLPQQACLQMLGVQGACKDNPGENARQLARIV

Pig                           IGTVGGGTSLLPQQACLQMLGVQGACKDNPGENARQLARIV

Bovine                        IGTVGGGTNLLPQQACLQMLGVQGACRDNPGENARQLARIV

Rabbit                        IGTVGGGTNLLPQQACLQMLGVQGACKDSPGENARQLARIV

Xenopus laevis                IGTVGGGTNLAPQQACLQMLGVQGASTETPGKNACQLAQIV

Drosophila                    VGTVGGGTGLPGQSACLEMLGVRGAHATRPGDNAKKLAQIV

Fission yeast                 VGTIGGGTVLEPQGAMLDLLGVRGAHMTSPGDNSRQLARVV
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 888 3-hydroxy-3-methylglutaryl-coenzyme A reductase
Topological domain 340 – 888 Cytoplasmic
Mutagenesis 807 – 807 G -> D. Does not affect hydroxymethylglutaryl-CoA reductase activity.



Literature citations
Limb girdle muscular disease caused by HMGCR mutation and statin myopathy treatable with mevalonolactone.
Yogev Y.; Shorer Z.; Koifman A.; Wormser O.; Drabkin M.; Halperin D.; Dolgin V.; Proskorovski-Ohayon R.; Hadar N.; Davidov G.; Nudelman H.; Zarivach R.; Shelef I.; Perez Y.; Birk O.S.;
Proc. Natl. Acad. Sci. U.S.A. 120:e2217831120-e2217831120(2023)
Cited for: VARIANT LGMDR28 ASP-822; CHARACTERIZATION OF VARIANT LGMDR28 ASP-822; INVOLVEMENT IN LGMDR28; FUNCTION; CATALYTIC ACTIVITY; BIOPHYSICOCHEMICAL PROPERTIES; ACTIVITY REGULATION;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.